心不全試験におけるエンドポイントとして患者の報告した結果
Javed Butler1,2, Muhammad Shariq Usman3,4, Charu Gandotra5
1Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, TX (J.B.).
Circulation
|April 14, 2025
まとめ
患者の報告したアウトカム (PRO) は心不全の治療に不可欠ですが,試験結果の解釈は困難です. この記事では,研究と臨床実務での使用を改善するために,PROの評価と分析に関する問題について説明します.
科学分野:
- 心臓病科
- 臨床研究
- 健康 に 関する 結果
背景:
- 心不全は世界中で何百万人もの人に影響し,入院や死亡率などの従来の指標に加えて,患者の報告された結果 (PRO) の認識が増加しています.
- 規制機関や専門社会はPROを認めているが,方法論が一貫していないため,心不全試験におけるその解釈は困難である.
- 課題は,PRO評価のタイミング/頻度に関するコンセンサスの欠如と,臨床的に重要な最小限の違いの定義です.
研究 の 目的:
- 心不全の臨床試験におけるPROデータ解釈の困難を解決する.
- PRO評価に関する課題,臨床的に重要な最小限の差異,および分析方法について議論する.
- 心不全の研究,規制評価,臨床実務におけるPROの有効な使用を促進する.
主な方法:
- 心不全のPRO評価と分析に関する問題の詳細な議論
- 具体例としてカンザスシティ心筋病質アンケート (KCCQ) を用いる.
- 平均差とレスポンダーの分析などの伝統的な分析方法を統計的制限のために批判します.
主要な成果:
- 心不全試験におけるPROの評価と分析の現在の方法は,しばしば解釈が困難である.
- PRO評価のタイミングと頻度に関する標準化されたプロトコルの欠如は,一貫したデータ収集を妨げています.
- 臨床的に重要な最小限の差異を確立することは,依然として大きな課題です.
結論:
- 心不全の研究における信頼性の高い解釈のために,PROの評価と分析を標準化することが不可欠です.
- 方法論的な課題に取り組むことで,介入の評価と臨床決定の指針としてのPROの有用性が向上します.
- PRO利用の改善は,心不全の管理において,より患者中心のケアにつながります.
関連する概念動画
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:22Heart Failure Drugs: β-Blockers
278
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
278
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
01:26Heart Failure Drugs: Inotropic Agents
424
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
424
01:22Heart Failure Drugs: Diuretics
294
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
294
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
38
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
38